HealthGovernment information and archivesHealth programs administration and fundingNeurological disordersPublic-private cooperationInternet, web applications, social mediaDrug therapyMedical researchResearch administration and fundingDepartment of Health and Human ServicesFood and Drug Administration (FDA)National Institutes of Health (NIH)
Why This Matters
This bill extends funding for ALS research and improves the review process for clinical trials related to ALS therapies.
If you are involved in ALS research, this bill secures funding for your work through 2031.
Who this affects
Patients with ALS · ALS researchers
What changes is this bill making?
1This bill extends funding for the Accelerating Access to Critical Therapies for ALS Act until 2031.
2It requires the Food and Drug Administration to publish a report on actions taken regarding ALS therapies within one year.
3The bill improves the review process for clinical trial grants by requiring manufacturers to share interim data.
4It clarifies the definition of clinical trials to include combined phase 2/3 trials and planned phase 3 trials.
